Estrella Immunopharma, Inc. current report, 30 September 2022

Full document

Business Context and Reporting Period

Filing: Form 8-K dated September 30, 2022, filed by TradeUP Acquisition Corp. (“UPTD”) and signed October 3, 2022. The filing reports UPTD’s entry into a definitive merger agreement with Estrella Biopharma, Inc., a preclinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS T-cell therapies for blood cancers and solid tumors.

Upon closing, TradeUP Merger Sub Inc. will merge with Estrella Biopharma, with Estrella Biopharma surviving as a wholly owned subsidiary of UPTD. UPTD is expected to change its name to Estrella Immunopharma, Inc.

Key Financial and Transaction Metrics

  • Merger consideration: $325 million, payable in newly issued UPTD common stock valued at $10.00 per share, implying 32.5 million shares before adjustments or other transaction effects.
  • Required cash: At least $20 million of aggregate cash at closing, including available trust-account funds after redemptions and specified expenses, transaction-financing proceeds, and qualifying company cash.
  • Transaction financing: At least $20 million must be completed before or at closing, including at least $15 million of equity financing and no more than $5 million of debt or equity-linked financing.
  • Net tangible assets: The combined company must have at least $5 million upon consummation of the merger.
  • Financial performance: The filing does not provide revenue, profit or loss, cash-flow, margin, debt, liquidity-balance, or operating-expense figures for either company.
  • Equity incentive plan: UPTD is required to adopt a post-closing plan covering shares equal to 10% of post-closing outstanding common stock, subject to specified exclusions, with a 5% annual evergreen increase unless waived.

Material Changes Versus the Prior Comparable Period

The filing is primarily a transaction announcement and does not present comparative financial statements or operating results. The material change is UPTD’s execution of the merger agreement and its proposed combination with Estrella Biopharma, including the planned issuance of merger consideration shares and required financing.

Guidance, Outlook, Risks, Contingencies, and Unusual Items

  • Closing remains subject to UPTD stockholder approval, satisfaction or waiver of customary representations and covenants, regulatory requirements, Nasdaq listing approval, minimum cash and net tangible-asset thresholds, and completion of the required financing.
  • The merger may be terminated under specified circumstances, including uncured breaches, failure to close by January 19, 2023 or an approved extension date, permanent legal prohibition, or failure to obtain required stockholder approval.
  • If closing cannot occur by January 19, 2023, Estrella Biopharma may be required to deposit an extension fee into UPTD’s trust account at the sponsors’ request. UPTD would issue a promissory note for the fee, payable in cash or convertible into UPTD common stock at $10.00 per share at closing.
  • Holders of more than 5% of Estrella Biopharma’s equity are expected to enter into six-month lock-up agreements. Half of the locked-up shares may be released earlier if UPTD’s stock closes at or above $12.50 per share for 20 trading days within a 30-trading-day period.
  • UPTD sponsors and certain initial stockholders agreed to vote their shares in favor of the transaction and support efforts to complete it.
  • Management identifies risks related to the companies’ limited operating history, the preclinical development stage, financing availability, stockholder redemptions, failure to satisfy Nasdaq requirements, transaction costs, failure to realize anticipated benefits, and failure to obtain approvals or otherwise close the merger.
  • The filing contains forward-looking statements regarding the transaction, future financing, cash position, operating results, market opportunity and potential benefits. No specific financial guidance is provided.

Most Important Facts for Investors to Verify

  1. Whether UPTD stockholders approve the merger and whether all other closing conditions are satisfied.
  2. The amount of cash remaining in UPTD’s trust account after redemptions and transaction expenses.
  3. Whether the required minimum $20 million financing is completed, including the $15 million minimum equity component.
  4. The final number of shares issued to Estrella Biopharma stockholders and the resulting ownership dilution, including the incentive-plan shares.
  5. Whether the combined company meets Nasdaq listing and minimum net tangible-asset requirements.
  6. Estrella Biopharma’s preclinical pipeline, development milestones, funding needs, financial statements and potential clinical, regulatory and commercialization risks, which are not detailed in this 8-K.
  7. The subsequent Form S-4, proxy statement/prospectus, amendments to the merger agreement, and any filings reporting closing, termination, financing or redemption results.